PSYCHEDELICS AND ENTACTOGENS IN PSYCHIATRY: PHARMACOLOGY, CLINICAL TRIAL EVIDENCE, AND REGULATORY CONSIDERATIONS
Global Journal of Research in Biology and Pharmacy October 31, 2025 DOI: 10.58175/gjrbp.2025.4.4.0176 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Interventions | Psilocybin 3 assisted psychotherapy |
| Key findings | The review reports that psychedelics and MDMA-assisted therapy show rapid, sustained symptom reductions in trials for depression and PTSD, with psilocybin holding FDA breakthrough designation and MDMA-assisted therapy completing positive phase 3 trials. It argues that regulatory review has raised methodological and safety concerns, and that challenges including blinding, expectancy effects, therapist training, and long-term safety require rigorous evaluation and oversight. |
Abstract
Psychedelics, including psilocybin, lysergic acid diethylamide, and dimethyltryptamine, and entactogens such as 3,4-methylenedioxymethamphetamine are being investigated for treatment-resistant depression, post-traumatic stress disorder, anxiety, and substance use disorders. These compounds act primarily through serotonin 5-HT2A receptor agonism (psychedelics) or monoamine release (MDMA), leading to acute alterations in consciousness that may enhance neuroplasticity and emotional processing. Randomized controlled trials have shown rapid and sustained reductions in depressive and post-traumatic stress symptoms following one or two assisted psychotherapy sessions. Psilocybin has received breakthrough therapy designation from the US FDA for treatment-resistant depression and major depressive disorder, while MDMA-assisted therapy for post-traumatic stress disorder has completed phase 3 trials with positive results, though regulatory review has raised methodological and safety concerns. This review critically examines the pharmacology, clinical evidence, and regulatory considerations for psychedelics and entactogens, focusing on literature through mid-2025. Challenges include blinding, expectancy effects, therapist training, and long-term safety. Future directions include dose optimization, identification of biomarkers, and integration into mental health care. While promising, these therapies require rigorous evaluation and careful regulatory oversight.